APLS:NSD-Apellis Pharmaceuticals, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 30.77

Change

+1.94 (+6.73)%

Market Cap

USD 2.28B

Volume

0.70M

Average Target Price

USD 57.29 (+86.17%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria diseases; and in Phase II clinical trials for the treatment of cold agglutinin disease, C3 glomerulopathy, IgA nephropathy, primary membranous nephropathy, and lupus nephritis. The company is also developing APL-9, which is in single ascending dose Phase I randomized, double-blind, and placebo-controlled clinical trials for the prevention of immune system activation coincident with adeno-associated virus for intravenous administration. Apellis Pharmaceuticals, Inc. was founded in 2009 and is based in Waltham, Massachusetts.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-25 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

+5.05 (+1.92%)

USD68.72B 34.32 27.50
REGN Regeneron Pharmaceuticals, Inc

+16.60 (+2.98%)

USD60.13B 21.90 16.92
SGEN Seattle Genetics, Inc

+5.52 (+3.08%)

USD31.19B N/A N/A
MRNA Moderna, Inc

+4.30 (+6.60%)

USD26.58B N/A N/A
RPRX Royalty Pharma plc

-0.16 (-0.40%)

USD25.36B 35.72 9.73
ALXN Alexion Pharmaceuticals, Inc

+2.41 (+2.15%)

USD24.64B 30.43 27.52
BGNE BeiGene, Ltd

+5.83 (+2.11%)

USD24.64B N/A N/A
GMAB Genmab A/S

+1.03 (+2.94%)

USD23.46B 28.02 3.06
IMMU Immunomedics, Inc

+0.06 (+0.07%)

USD19.69B N/A N/A
INCY Incyte Corporation

+1.48 (+1.74%)

USD18.80B 47.64 35.20

ETFs Containing APLS

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 0.49% 54% F 61% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 0.49% 54% F 60% D-
Trailing 12 Months  
Capital Gain 25.95% 58% F 74% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 25.95% 58% F 74% C
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 26.89% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 26.89% N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 51.48% N/A N/A N/A N/A
Risk Adjusted Return 52.24% N/A N/A N/A N/A
Market Capitalization 2.28B 86% B 81% B-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 10.40 17% F 12% F
Price / Cash Flow Ratio -10.82 69% D+ 82% B-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -240.56% 12% F 5% F
Return on Invested Capital -157.90% 13% F 5% F
Return on Assets -41.10% 26% F 8% F
Debt to Equity Ratio 416.50% 5% F 4% F
Technical Ratios  
Short Ratio 16.67 9% F 4% F
Short Percent 20.90% 8% F 10% F
Beta 1.15 67% D+ 48% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector